<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04465916</url>
  </required_header>
  <id_info>
    <org_study_id>EYP001-201</org_study_id>
    <nct_id>NCT04465916</nct_id>
  </id_info>
  <brief_title>Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Oral FXR Modulator EYP001a Combined With Nucleos(t)Ide Analogues (NA) in Virologically Suppressed Chronic Hepatitis B Patients to Improve Functional Cure Rates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enyo Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synteract, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eurofins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Enyo Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a
      experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically
      suppressed CHB patients to improve functional cure rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 49 eligible patients will be enrolled and randomized at approximately 14 study
      sites. Patients will be randomized prior to study drug (EYP001a or placebo and NA)
      administration on Day 1 in the ratio of 3:1 into 2 arms:

        -  Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)

        -  Control Arm: Placebo + NA daily (12 patients)

      The maximum total engagement duration for eligible patients in this study is up to 370 days:
      90 days screening, 112 days (16 weeks) treatment period and 168 days (24 weeks) follow-up.

      Patients enrolled in the study will be assessed as outpatients. Patient screening will occur
      no more than 90 days prior to the Day 1 visit. Eligible patients will undergo further
      assessments on Day 1 to qualify for study drug administration on Day 1.

      The visits during the study are planned as below:

        -  Screening visit: 12 weeks (90 days)

        -  16 weeks treatment period:

        -  Treatment Visit 1 (Week 1 [Day 1])

        -  Treatment Visit 2 (Week 2 [Day 14 ±3 days])

        -  Treatment Visit 3 (Week 4 [Day 28 ±3 days])

        -  Treatment Visit 4 (Week 6 [Day 42 ±3 days])

        -  Treatment Visit 5 (Week 8 [Day 56 ±3 days])

        -  Treatment Visit 6 (Week 10 [Day 70 ± 3 days])

        -  Treatment Visit 7 (Week 12 [Day 84 ± 3 days])

        -  Treatment Visit 8 (Week 14 [Day 98 ± 3 days])

        -  Treatment Visit 9 (Week 16 [Day 112±3 days])

        -  24 weeks safety follow-up period:

        -  Follow-up Visit 1 (Week 20 [Day 140 ±7 days])

        -  Follow-up Visit 2 (Week 28 [Day 196 ±7 days])

        -  Follow-up Visit 3 (Week 40 [Day 280 ±7 days]) Note: during follow-up patients are kept
           on NA until the end of the trial: Week 40 (consolidation Phase).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Triple blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg change</measure>
    <time_frame>16 weeks</time_frame>
    <description>Efficacy assessed as HBsAg change (Δ log10) from Day 1 to Week 16 of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBsAg responder rate change</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBsAg responder rate (change from baseline ≥ 1.0 on the log10 scale) at Week 16 of treatment and Weeks 20, 28 and 40 of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg responder rate change</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBsAg responder rate (change from baseline ≥ 0.5 on the log10 scale) at Weeks 12 and 16 of treatment and Weeks 20, 28 and 40 of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss rate</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBsAg loss rate (percent of patients with HBsAg &lt; lower limit of quantification [LLOQ]) at Week 16 of treatment and Weeks 20, 28 and 40 of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss rate</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBsAg loss rate (Proportion of results that are Target Not Detected versus Target Detected) at Week 16 of treatment and Weeks 20, 28 and 40 of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate HBsAg</measure>
    <time_frame>40 weeks</time_frame>
    <description>Relapse rate HBsAg (percent of patients who became negative [HBsAg &lt; LLOQ], then increased with HBsAg &gt; LLOQ) at Week 16 of treatment period and Weeks 20, 28 and 40 during follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic failure rate</measure>
    <time_frame>40 weeks</time_frame>
    <description>Virologic failure rate (breakthrough)2 of HBV-DNA (% patients with a confirmed quantifiable HBV DNA increase of ≥ 1log10 HBV DNA copies/mL above LLOQ3) assessed at Week 16 of treatment period and Weeks 20, 28 and 40 during follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV-pgRNA change</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBV-pgRNA change (Δ log10) from Day 1 to Weeks 4, 8, 12, 16 of treatment period and Week 40 of maintenance period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBcrAg change</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBcrAg change (Δ log10) from Day 1 to Weeks 4, 8, 12, 16 of treatment period and Week 40 of maintenance period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg quantification</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBeAg quantification for HBeAg pos patients and changes at Week 16 of treatment and Week 40 of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroscan VCTE change</measure>
    <time_frame>40 weeks</time_frame>
    <description>Fibroscan VCTE change from screening value to Weeks 16 and 40 or ET value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Adverse Events)</measure>
    <time_frame>40 weeks</time_frame>
    <description>Safety and Tolerability assessed as: AEs including serious adverse events [SAEs]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (EYP001a/placebo blood dosage)</measure>
    <time_frame>16 weeks</time_frame>
    <description>PK assessed as:
o Plasma concentration of EYP001a or any relevant active metabolites (as identified in an ongoing phase 1 study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD : C4</measure>
    <time_frame>40 weeks</time_frame>
    <description>PD markers: Plasma C4 (7α-hydroxy-4-cholesten-3-one)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: FGF19</measure>
    <time_frame>40 weeks</time_frame>
    <description>FGF19: Fibroblast Growth Factor 19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: BA</measure>
    <time_frame>40 weeks</time_frame>
    <description>Biles Acids (Plasma primary and secondary BAs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control Arm: Placebo + NA daily (12 patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EYP001a</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Are on stable NA therapy at least 12 months from the screening date (ETV or TDF)

          -  Has virally suppressed CHB:

        HBV DNA &lt;LLOQ and serum HBsAg &gt;100 IU/mL

          -  Has liver imaging to screen for hepatocellular carcinoma or concomitant
             pancreaticobiliary disease either in the prior 6 months or at screening.

          -  Is not of childbearing potential or, if of childbearing potential, is not pregnant as
             confirmed by a negative serum human chorionic gonadotropin test at screening and is
             not planning a pregnancy during the course of the study.

        Main Exclusion Criteria:

          -  Is an employee of a contract research organization (CRO), vendor, or Sponsor involved
             with this study.

          -  Has known hepatocellular carcinoma or pancreaticobiliary disease.

          -  Neutropenia (defined by two confirmed values within screening period of &lt;1500/μL).

          -  Has Gilbert syndrome.

          -  Shows evidence of worsening liver function, defined as either a confirmed (two
             assessments at least 3 days apart) increase &gt;2 ULN ALT or AST or an increase of &gt;1.5 ×
             first assessed value of TBL or associated with clinical signs or symptoms of liver
             impairment.

          -  Has known or suspected non-CHB liver disease

          -  History of cirrhosis or liver decompensation, including ascites, hepatic
             encephalopathy, or presence of oesophageal varices.

          -  Probable or possible F3 stage with a vibration controlled transient elastography
             (VCTE). Patients with normal baseline ALT and VCTE &gt;8.8 kPa are excluded. Patients
             with baseline ALT &gt;ULN (but &lt;2ULN per EC5) and who have VCTE &gt;10.5 kPa at baseline are
             excluded 11.

          -  Has known history of alcohol abuse or daily heavy alcohol consumption

          -  Has clinically relevant immunosuppression, including, but not limited to,
             immunodeficiency conditions such as common variable hypogammaglobulinemia.

          -  Has used anti-HBV medications other than NAs within 90 days prior to screening.

          -  Has any of the following exclusionary laboratory results at screening:

               1. Estimated glomerular filtration rate &lt;60 mL/min/1.73 m2 (the Modification of Diet
                  in Renal Disease formula).

               2. Thyroid-stimulating hormone &gt;1.5× ULN or abnormal free triiodothyronine or free
                  thyroxine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR04</last_name>
    <role>Principal Investigator</role>
    <affiliation>Busan, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR03</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR02</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR01</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL06</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kielce, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL05</last_name>
    <role>Principal Investigator</role>
    <affiliation>Łódź, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL04</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zawiercie, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL03</last_name>
    <role>Principal Investigator</role>
    <affiliation>Warszawa, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL02</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lublin, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL01</last_name>
    <role>Principal Investigator</role>
    <affiliation>Białystok, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site AU04</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site AU03</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site AU02</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brisbane, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site AU01</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javiera Kaiser</last_name>
    <phone>918041648996</phone>
    <email>Javiera.Kaiser@novotech-cro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site AU02</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javiera Kaiser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site AU01</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site AU03</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javiera Kaiser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site AU04</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javiera Kaiser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR04</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javiera Kaiser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR01</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javiera Kaiser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR02</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javiera Kaiser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR03</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javiera Kaiser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL01</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javiera Kaiser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL06</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL02</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL03</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javiera Kaiser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL04</name>
      <address>
        <city>Zawiercie</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL05</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javiera Kaiser</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

